A Study Evaluating Longidaza® Published in Urologia Journal: Combination Treatment Reduced the Risk of Chronic Prostatitis Recurrence Nearly Fourfold

Chronic prostatitis remains one of the most challenging urological conditions to treat: the disease frequently recurs even after antibacterial treatment and is often associated with impaired reproductive function. Results of a study conducted by Russian researchers and published in Urologia Journal [ 1 ] demonstrate that targeting bacterial biofilms can significantly improve treatment outcomes and reduce the risk of disease recurrence by nearly fourfold. Chronic prostatitis is among the most common urological disorders in men, affecting approximately 40% of patients [ 2 ] . Bacterial infections are one of the key factors contributing to disease development; however, standard antibiotic treatment does not always achieve complete resolution of inflammation [ 3 ] . The chronic course of prostatitis and its recurrent exacerbations are often associated with biofilms—specialized structures that protect bacteria from both antibiotics and the immune system. Biofilms may increase bacterial resistance to antibiotic treatment by as much as 1,000-fold [ 4 ] . As a result, the pathological process may become chronic, leading to prostate fibrosis and impaired fertility [ 5 ] . "The disruption of biofilms is becoming an increasingly important strategy in the treatment of chronic prostatitis. Our study demonstrated that adding bovhyaluronidase azoximer, a medication that effectively targets biofilms, to antibacterial treatment reduces the severity of inflammation and significantly decreases the risk of recurrence during the year following treatment," emphasized Leonid G. Spivak, Doctor of Medical Sciences, Professor at the Institute of Urology and Human Reproductive Health of Sechenov University.

The release as fetched from its publisher. petrovax.com ↗